The new pain treatments that may finally stem the need for opioids - New Scientist

Why talk and behaviour-based interventions that don't use any drugs, as well as genetic therapy and bacterial toxins, are promising new weapons in our fight against pain

Health 16 November 2022

By Stephani Sutherland

Anthrax bacteria in lung. Coloured scanning electron micrograph (SEM) of a cluster of anthrax bacteria (Bacillus anthracis) in a capillary of the lung. These rod-shaped, Gram-positive bacteria are highly pathogenic. Commonly an infection of livestock, B. anthracis is transmitted to humans by contact with contaminated animal hair, hides or excrement. Two forms of the disease occur: pneumonia in the lungs (woolsorter's disease), and cutaneous anthrax, which causes a large boil at the site of the bacteria's entry. Antibiotic treatment, if prompt, may be effective for the skin infection. Pulmonary anthrax is fatal in most cases. Magnification: x540 at 6x7cm size. x1750 at 7.5x9.5"

A cluster of anthrax bacteria

Science Photo Library

TENS of millions of people live with chronic and in some cases disabling daily pain in the US alone, in addition to those experiencing acute pain. Yet treatments for pain relief remain only partially effective and only work for some people.

For instance, paracetamol (acetaminophen) may have little or no effect on extreme pain and exceeding the recommended dose can be toxic to the liver. Similarly, ibuprofen and other non-steroidal anti-inflammatory drugs – which tackle the inflammation that presses on nerve endings and causes pain – have a range of side effects, including headaches and indigestion, as well as interacting with drugs used for several other conditions. This leaves opioids, which mimic the body's natural painkillers and are among the most effective form of pain relief.

Yet while opioids may work for many types of acute and chronic pain, they can be ineffective against others, and are associated with addiction and the risk of overdose. The opioid epidemic has cost hundreds of thousands of lives in the US and has underlined the need for alternative treatments. But as John Wood, a pain researcher at University College London, puts it: "There has been a tremendous succession of failures trying to make new analgesics."

For years, pharmaceutical companies had been looking for a way in through a single gene that might be vital for pain, he says. So, in 2006, when a team led by Geoff Woods at the University of Cambridge discovered such a gene, called SCN9A(see "What is pain, how does it work and what happens when …

Adblock test (Why?)

Comments

Post a Comment

Popular posts from this blog

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

Image
“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more Opioids in America, Part 3: The other side of the crisis - Greeley Tribune Posted: 31 Oct 2020 04:20 PM PDT Editor's Note: This is Part 3 of a three-part series looking into the opioid epidemic across the U.S., rehabilitation options in Weld County and stories from people who have overcome or are currently fighting addiction to opioids. Like many things, there's another side to the opioid crisis. While the addiction to opioids is a problem that needs to be addressed, people who are using the drugs exclusively as prescribed — and who still truly need it from a medical perspective — have been swept up in what some have seen as government's knee-jerk reaction to the crisis. In having their ability limited to get the drugs they need in order to function, many of these patients are left suffering debilitating pain. Richard Mark VanWormer w
Read more

“Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet” plus 4 more

Image
“Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet” plus 4 more Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet Evaluation of the novel coronavirus disease in Turkish children: Preliminary outcomes - Wiley Coronavirus recovery: Most common post-COVID signs which could indicate signs of long term trouble - Times of India What you – and doctors – should watch for if you have COVID-19 - The Conversation US Coronavirus in San Diego and California: Latest updates and news - CBS News 8 Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet Posted: 08
Read more

“Ground glass opacity: Causes, symptoms, and treatments - Medical News Today” plus 1 more

Image
“Ground glass opacity: Causes, symptoms, and treatments - Medical News Today” plus 1 more Ground glass opacity: Causes, symptoms, and treatments - Medical News Today Posted: 30 Mar 2021 03:14 AM PDT Ground glass opacity (GGO) refers to the hazy gray areas that can show up in CT scans or X-rays of the lungs. These gray areas indicate increased density inside the lungs. The term comes from a technique in glassmaking during which the surface of the glass is blasted by sand. This technique gives the glass a hazy white or frosted appearance. There are many potential causes of GGO, including infections, inflammation , and growths. One 2020 review also found that GGO was the most common anomaly among people with COVID-19-related pneumonia. This article will look at what GGO is, some of its causes, and its treatment options. GGO refers to gray areas that can show up in lung X-rays or CT scans . Normally, the lungs appear black
Read more